Abstract

Erythropoietin is one of the main regulators of haematopoiesis in the human and is being used more and more widely in the treatment of such clinical conditions as anaemia of chronic renal disease which would otherwise require transfusion. Recently, this approach has been extended to pregnant patients and the results have been encouraging. Fetal erythropoietin levels appear to be good indicators of anaemia and hypoxia which, if detected, allow for the identification of compromised fetuses. More data are emerging pointing to erythropoietin’s role in fetal central nervous system development and its potential protective role against hypoxia. This carries important implications for the obstetrician/gynaecologist, as erythropoietin is likely to play a major part in the diagnosis and treatment of certain maternal and fetal conditions.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.